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In recent years, there has been a tremendous and growing interest among researchers to investigate the role of
mircoRNA (miRNA) in normal cellular as well as in disease processes. miRNAs are a family of small non-coding
RNAs which were reported to regulate the expression of various oncogenes or tumor suppressor genes. The
expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to
assess tumor initiation, progression and response to treatment in cancer patients. This review summarizes: (i) the
current understanding of interactions between miRNAs and their target genes, (ii) recent advances in the
regulatory mechanisms that control the expression of genes related to carcinogenesis, and (iii) the role of
miRNAs in cancer diagnosis and therapy.
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MicroRNAs (miRNAs) are small non-coding regions in
RNAs of 20–22 nucleotides, which play an important
role in all biological pathways in multicellular organisms
including mammals [1]. Under normal physiological
conditions, miRNAs function in feedback mechanisms
by safeguarding key biological processes including cell
proliferation, differentiation and apoptosis [2,3]. De-
regulation of a single or small subset of miRNAs was
reported to have a profound effect on the expression pat-
tern of several hundred mRNAs [4,5] which propels the
cells towards transformation [6,7]. The human disease-
related miRNAs, viz., miR15 and miR16 at 13q14, were
first characterized in chronic lymphocytic leukemia [8,9].
Subsequently, elevated levels of tumor-associated miRNAs
were identified in the serum of patients with diffuse large
B-cell lymphoma [8,9]. Emerging evidence has also sug-
gested the involvement of long noncoding RNA (IncRNA)
in the development and progression of cancer [10] by
exerting their regulatory functions through specific inter-
actions with proteins, including epigenetic modifiers, tran-
scriptional factors/co-activators, and RNP complex
[11-13]. In this review, the role of miRNAs in carcinogen-
esis/cancer is discussed.Correspondence: kreddy@med.wayne.edu
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The biogenesis of miRNA is schematically presented in
Figure 1. Generally, it involves transcription of a pri-
miRNA precursor by RNA polymerase II which is subse-
quently processed in the nucleus by endonuclease
enzymes such as DROSHA and DGCR8 resulting in pre-
miRNA sequence consisting of approximately 80–100
nucleotides [14,15]. Exportin-5 was reported to assist in
the transport of pre-miRNAs from the nucleus to the
cytoplasm [16] where a cytoplasmic ribonuclease, Dicer,
cleaves it into double stranded mature miRNA [17].
Then, the mature miRNA duplex binds to Argonaute
(Ago) proteins forming RNA-induced silencing complex
(RISC) which then regulates the translation of comple-
mentary messenger RNA (mRNA). The mature miRNA
recognizes its complementary sequences in the 3′ un-
translated region (UTR) of their target mRNAs via seed
region, typically positions 2–7 in the miRNA. Recent
studies have suggested that miRNAs binds to 5′UTR or
open reading frame (ORF) of the target mRNA [18,19].
Since high complementarity is not required for regula-
tion, a single miRNA may target up to several hundred
mRNAs and the resulting aberrant miRNA expression
may affect a multitude of transcripts, which have pro-
found influence on cancer-related signaling pathways.Involvement of microRNAs in cancer
There were several reports indicating more than half of
the miRNAs genes are located in cancer-associateds an Open Access article distributed under the terms of the Creative Commons
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Figure 1 MicroRNA biogenesis pathways and their regulation: a schematic representation depicting the miRNA biogenesis pathway. The
primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA by the microprocessor complex Drosha-DGC8 in the
nucleus. The resulting precursor hairpin, the pre-miRNA, is exported from the nucleus by exportin-5-Ran-GTP. In the cytoplasm, the RNase Dicer form
complex with the double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to its mature length. The functional strand of the mature
miRNA is loaded together with Argonaute (Ago2) proteins into the RNA-induced silencing complex (RISC), where it targets mRNAs through mRNA
cleavage, deadenylation or translational repression, where as passenger strand (3′———————5′) is degraded.
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sion data from a wide spectrum of cancer tissues/cells
have shown that aberrant miRNA expression is a rule ra-
ther than exception. The involvement and the role
played by miRNAs in many types of cancers were re-
ported in different types of cancers, including breast,
colon, gastric, lung, prostate and thyroid [20-24]. The
peer-reviewed scientific literature on miRNAs is huge
and indicated by ~15,943 PubMed hits as of March 2015
and, their role in cancer is very diverse both in terms of
the disease and experimental approaches used by the in-
vestigators. Although the overwhelming majority of pub-
lished papers focus on individual mRNA target, most
miRNAs can exert their effects by targeting multiple
mRNAs, some of which may reside in the same cellular
pathway. Some studies have also shown that there were re-
dundant with distinct sequences which can repress the
same target mRNA [25]. Mouse models featuring miRNA
overexpression or ablation have demonstrated causal links
between miRNAs and cancer development [26,27].
Bioinformatics methods to predict paradigms
The bioinformatics methods which are currently used to
predict paradigms suggested that the interaction of miR-
NAs with their targets (candidate mRNAs) depends on
the sequence, and evolutionary conservation [28,29].Such methods identifies tens or hundreds of targets for
each miRNA: however, the false positive rates were re-
ported to be high [30]. Therefore, investigations examin-
ing the gain and loss of function of miRNAs are still
needed to confirm the predictions. Evaluation of the as-
sociation between a particular miRNA to a specific type
of cancer is additionally complicated by the genetic di-
versity of tumors, and in cell lines derived from different
tumors. A particular miRNA may have exhibited its
oncogenic function in some types of cancers whereas
the same miRNA was reported to act as a tumor sup-
pressor in other cancers. Some such examples include:
(i) miR-29, specifically miR-29a/-b/-c was reported as an
oncogene in breast cancer while the same miRNA-29
acted as a tumor-suppressor gene in lung tumors
[31,32]; (ii) loss of miR-23b conferred proliferative ad-
vantage and promoted bladder cancer cell migration and
invasion [33] while knocking down the expression of
same miRNA-23b in renal cell carcinoma (RCC) cell
lines induced apoptosis and reduced invasive capabilities
[34]. One possible explanation is that the same miRNA
can participate in distinct pathways, having different ef-
fects on cell survival, growth and proliferation that are
dependent on the cell type and pattern of gene expres-
sion. Furthermore, the potential for miRNA-mediated
regulation of gene expression is enormous since ~60% of
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NAs [35]. Hence, it is imperative to verify the phenotype
and function of miRNA in appropriate animal and hu-
man cancer cell models.
Abnormal expression of miRNA
There were several reports indicating widespread disrup-
tion of miRNA expression levels in numerous diseases, in-
cluding cancer. Tumor tissues and cultured tumor cells
often exhibit significantly reduced expression levels of ma-
ture miRNAs [36]. Different mechanisms for the aberrant
expression of miRNA were documented. Three of them,
viz., (i) genetic alterations and single nucleotide poly-
morphism (SNP), (ii) epigenetic silencing and (iii) defects
in the miRNA biogenesis pathway, are discussed below.
(i) Genetic alterations and SNP: Complete mapping of
human miRNA genes revealed that a great majority
of the miRNAs were associated with fragile sites,
cancer-specific translocation breakpoints, repetitive
sequences and CpG islands [37]. However, some
studies have indicated such association is not
straight-forward and appears to be dependent on
the specific type of cancer [38]. Furthermore, the
existence of polymorphism in single nucleotides
(SNPs) is widely known and, evidence has been
presented suggesting the influence of SNPs on
miRNA targets in cancer-related pathways [39].
A gain in function due to SNP may enhance its
interaction with miRNA target and thus, enhance
its regulatory function such as a tumor suppressor
gene. In contrast, loss in function due to SNP may
result in increased expression of miRNA, which
then acts as an oncogene [40]. Additionally, SNPs in
target sites of miRNAs may also result in the escape of
degradation by miRNA [41]. All these observations
suggested that SNPs may be one of the contributing
factors in the regulation of biogenesis and
functionality of miRNAs.
(ii)Epigenetic regulation of miRNA expression: Several
research groups have investigated whether
epigenetics, i.e., hyper- or hypo-methylation (an
early event in carcinogenesis), play a role and
influence the activity of miRNA genes [42-44] since
the expression of miRNA genes, especially those
located near CpG islands, tends to be affected more
readily by methylation processes [42,43,45]. In
scientific literature, there were several examples of
DNA methylation processes influencing the activity
of miRNAs. Some such examples were as follows.
(i) The comparative analysis data in colon cancer
cell line indicated that the expression of about 10%
miRNAs tested were regulated by DNA methylation
and that partial methylation reductions were notsufficient for the recovery of miRNA [46]. (ii) Screening
investigations in colorectal cancers identified
(a) epigenetic silencing of miR-34b and miR-34c due to
hyper-methylation of neighboring CpG islands and
(b) alteration in the methylation process affected miR-9
family genes [47]. (iii) Methylation of miR-9-1 was
reportedly associated with lymph node metastasis in
colorectal cancer cells (CRC) [48]. (iv) Significant and
positive correlation between methylation of miR-200c/
141 and invasive capacity of breast cancer cells [49]. (v)
Methylation of miR-200c/141 is tightly associated with
the invasive capacity of breast cancer cells [49]. (vi) In
non-small cell lung cancer, promoter methylation was
related with loss of miR-200c expression which in turn
was associated with poor differentiation, lymph node
metastasis and weaker E-cadherin expression [50]. In
addition to DNA methylation, histone acetylation was
also reported to be another epigenetic phenomenon in
deregulated cancers. In breast cancer cells, histone
deacetylase inhibition was shown to result in
alteration in miRNA levels [51]. In bladder cancer cells,
a combined treatment with 5-aza-2′-deoxycytidine
(5-Aza-CdR) and histone deacetylase (HDAC) inhibitor
4-phenylbutyric acid (PBA) had a significant effect on
multiple miRNAs among which miR-127 was most
differentially expressed [45]. Specific induction/ac-
tivation of miRNA-127 by 5-Aza-CdR and PBA
suppressed the transcription of the zinc-finger
repressor BCL6 gene and thus induced apoptosis in
human cancer cells [45].
(iii)Defects in the miRNA pathway: In humans, the
majority of miRNAs are encoded by introns of
non-coding or coding transcripts. However, some
miRNAs were reported to be encoded by exonic
regions. The genes controlling miRNA are often
clustered and transcribed as polycistronic messages
or excised from mRNAs [52]. The precise locations
of promoters for most miRNA genes are not yet
mapped but, they can be inferred from collective
analysis of CpG islands, RNA sequencing and
chromatin immune-precipitation followed by
ChIP-sequencing [53]. Numerous Pol-II associated
transcription factors were reported to activate or
repress several miRNA genes. The abundance of some
miRNAs were also shown to be regulated at the RNA
stability level [54]. Recently, Ser/Thr protein kinase/
endoribonuclease IRE1α has been shown to be
activated by endoplasmic reticulum stress and cleaved
some selected pre-miRNAs, such as pre-miR-17,
pre-miR-34a, pre-miR-96 and pre-miR125b, leading to
translational reduction in the pro-apoptotic caspase 2
[55]. Previous reports have also indicated that Myc
gene is responsible for up-regulating the oncogenic
miR-17-92 cluster. The principal effect of Myc
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miRNA [56,57] as well as down-regulation of several
anti-proliferative, pro-apoptotic and tumor suppressor
effects such as let-7, miR15a/16-1, miRNA-26a and
miR-34 family members [58]. Similarly, activation of
Ras gene was shown to result in repression of the
miR-143/145 cluster in k-Ras mutant pancreatic
cancers [59]. The p53 tumor suppressor gene was
reported to regulate the expression of several
miRNAs, such as miR34, miR-200. miR 15/16, etc.
[60,61] and the miR34 family targets cyclin D and E2,
CDK4, CDK6, Myc and BCl2 all of which play a major
role in promoting cell proliferation, apoptosis and,
these observations suggested the possibility that
p53-induced miR-34 may negatively regulate cell
growth [60,62].
miRNA in cancer diagnosis and therapy
Microarray analysis of oligonucleotide miRNA is the most
commonly used high-throughput technique for the assess-
ment of the expression levels of hundreds of miRNA in a
large number of cancer-specific cell types [63,64]. Studies
using miRNA profiling have shown significantly different
miRNA profiles in cancer cells compared with those in
normal cells in the same tissue. Hierarchical clustering
analyses also indicated that miRNA signature profiling en-
abled the tumor tissue samples to be grouped into a spe-
cific origin. Several genome-wide profiling studies have
been performed on various types of cancers, such as breast,
chronic lymphocytic leukemia, colon, lung, glioblastoma
and thyroid papillary carcinoma, etc. [21,22,65-68]. Ana-
lysis of miRNAs in 76 breast cancer and 10 normal breast
tissue samples had identified significantly dysregulated
miR-125b, miR-145, miR-21 and miR-155: from such ana-
lysis, 15 such analyses could correctly predict whether the
sample was normal or tumor breast tissue [22]. In a separ-
ate and similar investigation using breast cancer tissue, let-
7d, miR-210 and miR-221 were found to be down-
regulated in the ductal carcinoma in situ while they were
up-regulated in the invasive transition [69].
Non-invasive and inexpensive methods
Researchers are focusing on the examination of body
fluids such as plasma, serum, urine and saliva to deter-
mine the circulating levels of miRNAs and to evaluate if
they can be used as diagnostic, prognostic and predictive
biomarkers in cancer. Such studies have attracted a great
deal of attention because of minimally invasive processes
to examine miRNA using qPCR. In the serum of pros-
tate cancer patients, the expression levels of pre-selected
oncogenic miR-26a, miR-195 and let-7i were shown to be
up-regulated compared to those in individuals with benign
prostate hyperplasia (BPH) [70]. Similarly, the prognostic
value of increased expression levels of circulating miR-141and miR-375 correlating with low-risk through high-risk
and from localized to metastatic prostate cancer was doc-
umented [71,72]. The signature miRNAs, miR-28-3p,
miR-30c, miR-92a, miR-140-5p, miR-451 and miR660 in
the plasma were found to be deregulated 1–2 years prior
to diagnosis of lung cancer and thus, indicated their use in
prediction as well as diagnosis [73]. miR-27b, miR-158a,
miR-326 signature or miR-200c in the serum of colon can-
cer patients were found to be useful to identify metastatic
tumors [74,75]. The miR-125b and miR-155 levels in the
serum of breast cancer patients were found to be useful
for diagnosis, assessing chemotherapeutic response as well
as in prognosis [76,77]. Until recently, miRNA analyses
were performed using qRT-PCR and microarray-based ap-
proaches. NGS is now emerging as a cost-effective option
while bioinformatics analyses are no longer a major prob-
lem for continued usage [78,79].
Clinical trials
The increasing understanding of the molecular alter-
ations underlying carcinogenesis and cancer had created
opportunities to use miRNAs as diagnostic and prognos-
tic indicators. Many signature miRNAs have been identi-
fied, and their use has been increasingly investigated in
clinical trials in several countries including USA. For ex-
ample: (i) circulating miRNA are used in breast cancer
as biomarkers to examine therapeutic response (https://
clinicaltrials.gov/ct2/show/NCT01722851); (ii) miR-10b
is used in Glioma as biomarker to grade the tumor, sur-
vival and genotypic variation (https://clinicaltrials.gov/
ct2/show/NCT01849952); (iii) miR-29 family (miR-29a/-
b/-c) is used to investigate the role of Twist-1-mediated
metastasis in Head and neck squamous cell carcinoma
(https://clinicaltrials.gov/ct2/show/NCT01927354); (iv) cir-
culating levels of miRNAs are evaluated as biomarker of
response to treatment in Ovarian cancer (https://clinicaltrials.
gov/ct2/show/NCT01391351); (v) multiple miRNAs are
investigated to examine the response to chemotherapy in
Non-small-cell lung cancer (https://clinicaltrials.gov/ct2/
show/NCT00864266), etc.
Conclusion
So far, there have been significant scientific research
findings indicating the utility of miRNAs as biomarkers
for prediction, diagnosis and prognosis. Evidence is also
emerging suggesting that inhibition of oncogenic miR-
NAs or substitution of tumor suppressive miRNAs could
be used to develop novel treatment strategies. The exten-
sive information thus far available in the peer-reviewed
scientific publications has been extremely useful to pro-
vide guidance for further investigations. Comprehensive,
carefully designed, multi-centered, retrospective and pro-
spective studies involving large cohorts in the same and
independent laboratories/clinics comparing and validating
Reddy Cancer Cell International  (2015) 15:38 Page 5 of 6the data within a similar type of cancer are warranted.
Besides, investigations using minimally invasive methods
to collect blood, saliva and urine are extremely important
for the development of reliable and cost-effective miRNA-
based technology for routine use in the clinics for early
cancer diagnosis/detection and therapeutic assessment/
prognosis.
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